Replies to post #17310 on Aurinia Pharmaceuticals Inc (AUPH)

[Watsonturtle]

Interesting ... thanks for sharing. The KDIGO PR and Executive summary emphasize two big reasons for updating the KDIGO clinical practice guidelines quicker than most expected: (1) the novel add-on therapies and in particular VOC/LUP approved by FDA (hard to ignore the results shown in the patient registry for LN patients treated with VOC/Lup both as initial therapy in that it acts fast in reducing UPRC and increasing eGRF and works well as maintenance therapy -- ergo: VOC/Lup gets KDIGO's high certainty of evidence rating); and (2) LN is an aggressive, devastating disease that requires immediate treatment to prevent permanent damage and potential loss of kidneys. I have seen the devastating nature of kidney disease first hand in my family. Thank God for Auph's investment in solving LN after more than 20 years of failed attempts by others including BP to solve LN. WT